JZUS - Journal of Zhejiang University SCIENCE

Journal of Zhejiang University SCIENCE B

Accepted manuscript available online (unedited version)

Constructing a PANoptosis-based prognostic signature to evaluate the immune landscape and therapy response in clear cell renal cell carcinoma

Author(s): Yu DONG¹, Zitong YANG¹, Zhinan XIA^1, ², Jiahao LIAO¹, Zhiming CUI^<3/sup>, Shenhao XU¹, Bing LIU¹, Liangliang REN¹, Tengda WANG⁴, Wei GUO¹, Shuwen WANG¹, Yuyong WANG^5, ⁶, Cheng ZHANG¹
Affiliation(s): ¹Department of Urology, the Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu 322000, China; more
Corresponding email(s): b1518118@zju.edu.cn, zhangcheng13836182568@zju.edu.cn
Key Words: PANoptosis; ccRCC; Prognosis; Tumor immune microenvironment; Immunotherapy response

Share this article to： More <<< Previous Paper \|Next Paper >>>

Yu DONG¹, Zitong YANG¹, Zhinan XIA^1,², Jiahao LIAO¹, Zhiming CUI^{<3/sup>, Shenhao XU¹, Bing LIU¹, Liangliang REN¹, Tengda WANG⁴, Wei GUO¹, Shuwen WANG¹, Yuyong WANG^5,⁶, Cheng ZHANG¹. Constructing a PANoptosis-based prognostic signature to evaluate the immune landscape and therapy response in clear cell renal cell carcinoma[J]. Journal of Zhejiang University Science B,in press.Frontiers of Information Technology & Electronic Engineering,in press.https://doi.org/10.1631/jzus.B2400132}

@article{title="Constructing a PANoptosis-based prognostic signature to evaluate the immune landscape and therapy response in clear cell renal cell carcinoma",
author="Yu DONG¹, Zitong YANG¹, Zhinan XIA^1,², Jiahao LIAO¹, Zhiming CUI^{<3/sup>, Shenhao XU¹, Bing LIU¹, Liangliang REN¹, Tengda WANG⁴, Wei GUO¹, Shuwen WANG¹, Yuyong WANG^5,⁶, Cheng ZHANG¹",
journal="Journal of Zhejiang University Science B",
year="in press",
publisher="Zhejiang University Press & Springer",
doi="https://doi.org/10.1631/jzus.B2400132"
}}

%0 Journal Article
%T Constructing a PANoptosis-based prognostic signature to evaluate the immune landscape and therapy response in clear cell renal cell carcinoma
%A Yu DONG¹
%A Zitong YANG¹
%A Zhinan XIA^1
%A²
%A Jiahao LIAO¹
%A Zhiming CUI^{<3/sup>
%A Shenhao XU¹
%A Bing LIU¹
%A Liangliang REN¹
%A Tengda WANG⁴
%A Wei GUO¹
%A Shuwen WANG¹
%A Yuyong WANG^5
%A⁶
%A Cheng ZHANG¹
%J Journal of Zhejiang University SCIENCE B
%P
%@ 1673-1581
%D in press
%I Zhejiang University Press & Springer
doi="https://doi.org/10.1631/jzus.B2400132"}

TY - JOUR
T1 - Constructing a PANoptosis-based prognostic signature to evaluate the immune landscape and therapy response in clear cell renal cell carcinoma
A1 - Yu DONG¹
A1 - Zitong YANG¹
A1 - Zhinan XIA^{1
A1 -}²
A1 - Jiahao LIAO¹
A1 - Zhiming CUI^{<3/sup>
A1 - Shenhao XU¹
A1 - Bing LIU¹
A1 - Liangliang REN¹
A1 - Tengda WANG⁴
A1 - Wei GUO¹
A1 - Shuwen WANG¹
A1 - Yuyong WANG^{5
A1 -}⁶
A1 - Cheng ZHANG¹
J0 - Journal of Zhejiang University Science B
SP -
EP -
%@ 1673-1581
Y1 - in press
PB - Zhejiang University Press & Springer
ER -
doi="https://doi.org/10.1631/jzus.B2400132"}

Abstract
Chinese Summary
Academic Network
Reviewer Comment

Abstract: Objective: To identify PANoptosis-related genes (PRGs) in ccRCC for patient stratification and prognosis prediction. Methods: We used differential expression analysis and weighted gene co-expression network analysis (WGCNA) to identify ccRCC-specific PRGs. A prognostic model, the PANoptosis-index (PANI), was constructed using LASSO and Cox regression. The PANI model, comprising PRGs, was validated through single-cell RNA sequencing (scRNA-seq), immunohistochemistry, and RT-qPCR. Patient cohorts were categorized into high- and low-PANI groups, and the model's performance was appraised using various metrics. External validation was performed with the E-MTAB-1980 dataset. Functional and gene set enrichment analyses distinguished biological differences between groups. Mutational landscapes and tumor immune microenvironments were compared. Sensitivity to immunotherapy and antineoplastic drugs was also predicted using PANI. Proliferation and migration capabilities of ZBP1 were assessed by CCK-8 and transwell assays. Results: We identified five PRGs (ZBP1, TNFSF14, CDKN3, PTHLH, and HMOX1) comprising PANI, independently associated with ccRCC patient prognosis. The PANI-based nomogram, integrated with clinical factors, demonstrated high predictive accuracy for prognosis. High-PANI patients exhibited distinct co-mutation patterns in ccRCC driver genes and lower survival probabilities, with an enriched immune-related functional profile, indicating an activated immune environment. These patients also showed increased sensitivity to immunotherapy and antineoplastic drugs. The knockdown of ZBP1, a key PRG in the PANI, significantly reduced ccRCC cell proliferation and migration. Conclusions: PANI provides precise prognosis and immunotherapy response predictions for ccRCC patients, facilitating individualized treatment strategies.

Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article

Reference

Open peer comments: Debate/Discuss/Question/Opinion

<1>

- Go to

Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article

Reference